Rucaparib (formerly known as AG-014699 and PF-01367338) is a potent small-molecule inhibitor of PARP-1, PARP-2, and PARP-3 that is being developed for the treatment of ovarian cancer and other tumour types associated with homologous recombination deficiency (HRD), including BRCA1 and BRCA2 mutations (Thomas et al, 2007; Drew et al, 2011; Swisher et al, 2017). This evidence concerns the gene PARP1 and ovarian cancer.